



SPAFID
CONNECT

Informazione Regolamentata n. 20106-56-2021	Data/Ora Ricezione 12 Novembre 2021 16:21:15	Euronext Star Milan
---	--	---------------------

Societa' : PHARMANUTRA
Identificativo : 154142
Informazione
Regolamentata
Nome utilizzatore : PHARMANUTRAN02 - Lacorte Roberto
Tipologia : REGEM; 3.1
Data/Ora Ricezione : 12 Novembre 2021 16:21:15
Data/Ora Inizio : 12 Novembre 2021 16:21:16
Diffusione presunta
Oggetto : CS - PHARMANUTRA SPA Interim
Financial Report as of 30 September 2021

Testo del comunicato

Vedi allegato.

PHARMANUTRA S.P.A.: INTERIM FINANCIAL REPORT AS OF 30 SEPTEMBER 2021

Pisa, 12 November 2021 - PharmaNutra S.p.A. (MTA; Ticker PHN) announces that the Interim Financial Report as of 30th September 2021, as approved by the Board of Directors of the Company on November 8th 2021, is available at the Company's registered office, on PharmaNutra S.p.A. website (www.pharmanutra.it, section *Investor Relations*) and on the authorized storage mechanism "eMarket Storage" available on the website (www.emarketstorage.it).

PharmaNutra S.p.A.

Established and led by Chairman Andrea Lacorte and Vice Chairman Roberto Lacorte, PharmaNutra is a company established in 2003 that develops unique nutritional supplements and innovative medical devices, taking care of the entire production process, from proprietary raw materials to the finished product. The effectiveness of the products is demonstrated by a number of scientific evidences, including more than 140 publications. The Group distributes and sells in Italy and abroad. In Italy, the sales activity is carried out through a network of over 150 Scientific Sales Representatives at the service of the medical class, also dedicated to the exclusive marketing of PharmaNutra products to pharmacies throughout the country. Sales abroad are guaranteed in over 50 countries through 39 partners selected among the leading pharmaceutical companies. PharmaNutra is a leader in the production of iron-based nutritional supplements under the brand name SiderAL[®], for which it boasts key patents for the Sucrosomial[®] Technology. Over the years, the Group has developed a precise strategy for the management and production of intellectual property, based on the integrated management of all components: proprietary raw materials, patents, trademarks and clinical evidence.

PharmaNutra.it

Per maggiori informazioni:

PharmaNutra S.p.A.

Via Delle Lenze, 216/b - 56122 Pisa
Tel. +39 050 7846500
investorrelation@PharmaNutra.it

Internal Press Office
press@calabughi.com

Press Office - Spriano Communication & Partners

Via Santa Radegonda, 16 - 20121 Milan
Tel. +39 02 83635708

Matteo Russo
mrusso@sprianocommunication.com
Cristina Tronconi
ctrnconi@sprianocommunication.com

Fine Comunicato n.20106-56

Numero di Pagine: 3